Work

Effects of Mulberry Leaf Supplementation on Cardiometabolic Markers: A Systematic Review and Meta-Analysis

Year: 2026
Type: preprint
Abstract: Background . Cardiometabolic dysfunction complicates diabetes management through impaired glycemic control, insulin resistance, and dyslipidemia. We evaluated the effects of mulberry leaf and its extract (ML/MLE) on glycated hemoglobin (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), and low-density lipoprotein cholesterol (LDL-C). Methods . This systematic review and meta-analysis was preregistered on the Open Science Framework (n3bct). Randomized controlled trials were identified from ClinicalTrials.gov, Cochrane CENTRAL, PubMed, and PubMed Central. Trials comparing ML/MLE with control for at least 4 weeks and reporting HbA1c were eligible. Statistical meta-analysis was performed in RevMan 5.4.1 using random-effects models. To account for baseline HbA1c, HbA1c effects were examined by baseline glycemic subgroup and contextualized against oral glucose-lowering studies at comparable baseline levels using study-level regression. Results . Eight randomized trials with 440 analyzed participants were included; the sample-size-weighted mean baseline HbA1c was 7.15%. ML/MLE reduced HbA1c versus control (MD -0.22 percentage points, 95% CI -0.39 to -0.06; p = 0.009). Baseline-stratified point estimates were 0.00 percentage points in non-diabetic, -0.14 in prediabetic, and -0.42 in diabetic trials. HOMA-IR decreased significantly in two trials (MD -0.64, 95% CI -1.27 to -0.02; p = 0.04; I² = 18%). LDL-C showed a non-significant pooled decrease (MD -6.21 mg/dL, 95% CI -15.37 to 2.94; p = 0.18; I² = 0%), with a concordant directional trend across all four trials. Seven of eight HbA1c estimates fell within the 50% prediction interval of oral-agent studies at comparable baseline HbA1c; the remaining estimate fell within the 80% interval. Conclusions . ML/MLE showed promising effects on glycemic control and insulin resistance, with the largest HbA1c reduction in diabetic-baseline trials. The LDL-C signal was directionally favorable but imprecise. Baseline-adjusted comparison with oral glucose-lowering studies supports the clinical plausibility of the HbA1c effect without establishing therapeutic equivalence. Larger, longer trials using standardized preparations are needed to confirm the secondary outcomes and define reproducible dosing.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7214003465
Cites: 26
Cited by:
Related to: 10